Fungal infections of the skin and nail: new treatment options

References

• Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol 2010;28(2):197-201
   PubMedGoogle Scholar
• Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia 2008;166(5-6):335-52
   PubMed Web of Science ®Google Scholar
• Squeo RF, Beer R, Silvers D, et al. Invasive Trichophyton rubrum resembling blastomycosis infection in the immunocompromised host. J Am Acad Dermatol 1998;39(2 Pt 2):379-80
   PubMedGoogle Scholar
• Cremer G, Bournerias I, Vandemeleubroucke E, et al. Tinea capitis in adults: misdiagnosis or reappearance? Dermatology 1997;194(1):8-11
   PubMedGoogle Scholar
• Elewski BE, Hughey LC, Sobera JO, Hay R. Fungal diseases. In: Bolognia JL, editor. Dermatology. Elsevier; Spain: 2012. p. 1252-4
   Google Scholar
• Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med 1999;153(5):483-6
   PubMedGoogle Scholar
• Fuller LC, Child FJ, Midgley G, Higgins EM. Diagnosis and management of scalp ringworm. BMJ 2003;326(7388):539-41
   PubMedGoogle Scholar
• Ilkit M. Favus of the scalp: an overview and update. Mycopathologia 2010;170(3):143-54
   PubMed Web of Science ®Google Scholar
• Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 2011;64(4):663-70
   PubMedGoogle Scholar
• Kakourou T, Uksal U; European Society for Pediatric D. Guidelines for the management of tinea capitis in children. Pediatr Dermatol 2010;27(3):226-8
   PubMedGoogle Scholar
• Gonzalez U, Seaton T, Bergus G, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev 2007(4):CD004685
   Google Scholar
• Smith KJ, Neafie RC, Skelton HG 3rd, et al. Majocchi’s granuloma. J Cutan Pathol 1991;18(1):28-35
   PubMedGoogle Scholar
• Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989;28(6):410-12
   PubMed Web of Science ®Google Scholar
• Faergemann J, Mork NJ, Haglund A, Odegard T. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol 1997;136(4):575-7
   PubMed Web of Science ®Google Scholar
• Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007(3):CD001434
   PubMed Web of Science ®Google Scholar
• Bell-Syer SE, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2012;10:CD003584
   PubMedGoogle Scholar
• Perez C, Colella MT, Olaizola C, et al. Tinea nigra: report of twelve cases in Venezuela. Mycopathologia 2005;160(3):235-8
   PubMedGoogle Scholar
• Badali H, Carvalho VO, Vicente V, et al. Cladophialophora saturnica sp. nov., a new opportunistic species of Chaetothyriales revealed using molecular data. Med Mycol 2009;47(1):51-62
   PubMed Web of Science ®Google Scholar
• Hughes JR, Moore MK, Pembroke AC. Tinea nigra palmaris. Clin Exp Dermatol 1993;18(5):481-2
   PubMedGoogle Scholar
• Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43(2 Pt 1):244-8
   PubMed Web of Science ®Google Scholar
• Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004;50(5):748-52
   PubMed Web of Science ®Google Scholar
• Romano C, Gianni C, Difonzo EM. Retrospective study of onychomycosis in Italy: 1985-2000. Mycoses 2005;48(1):42-4
   PubMedGoogle Scholar
• Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis 1996;22(Suppl 2):S128-32
   Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11(3):415-29
   PubMed Web of Science ®Google Scholar
• Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43(4 Suppl):S70-80
   PubMed Web of Science ®Google Scholar
• Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007;157(1):149-57
   PubMed Web of Science ®Google Scholar
• Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992;17(Suppl 1):44-9
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;68(4):600-8
   PubMed Web of Science ®Google Scholar
• Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995;32(5 Pt 1):750-3
   PubMed Web of Science ®Google Scholar
• Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991;30(8):586-9
   PubMedGoogle Scholar
• Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004;150(3):537-44
   PubMed Web of Science ®Google Scholar
• Crespo Erchiga V, Ojeda Martos A, Vera Casano A, et al. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol 2000;143(4):799-803
   PubMedGoogle Scholar
• Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor. Int J Dermatol 1998;37(9):648-55
   PubMedGoogle Scholar
• Terragni L, Lasagni A, Oriani A. Pityriasis versicolor of the face. Mycoses 1991;34(7-8):345-7
   PubMedGoogle Scholar
• Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician 2005;72(5):833-8
   PubMed Web of Science ®Google Scholar
• Freedberg IM, Eisen AZ, Wolf K, et al. Fitzpatrick’s dermatology in general medicine. 6th edition. McGraw-Hill; New York, NY, USA: 2003. p. 2006-18
   Google Scholar
• Guitart J, Woodley DT. Intertrigo: a practical approach. Compr Ther 1994;20(7):402-9
   PubMedGoogle Scholar
• Mayser P. Mycotic infections of the penis. Andrologia 1999;31(Suppl 1):13-16
   PubMedGoogle Scholar
• David LM, Walzman M, Rajamanoharan S. Genital colonisation and infection with Candida in heterosexual and homosexual males. Genitourin Med 1997;73(5):394-6
   PubMedGoogle Scholar
• Wiener S. Diagnosis and management of Candida of the nipple and breast. J Midwifery Womens Health 2006;51(2):125-8
   PubMedGoogle Scholar
• Amir LH, Garland SM, Dennerstein L, Farish SJ. Candida albicans: is it associated with nipple pain in lactating women? Gynecol Obstet Invest 1996;41(1):30-4
   PubMedGoogle Scholar
• Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol 2005;53(6):931-51; quiz 52-4
   PubMedGoogle Scholar
• Ahmed AO, van Leeuwen W, Fahal A, et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis 2004;4(9):566-74
   PubMed Web of Science ®Google Scholar
• van de Sande WW. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis 2013;7(11):e2550
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Esterre P, Perez-Blanco M, et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2009;47(1):3-15
   PubMed Web of Science ®Google Scholar
• Lopez Martinez R, Mendez Tovar LJ. Chromoblastomycosis. Clin Dermatol 2007;25(2):188-94
   PubMedGoogle Scholar
• Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin North Am 1988;2(4):925-38
   PubMedGoogle Scholar
• Burges GE, Walls CT, Maize JC. Subcutaneous phaeohyphomycosis caused by Exserohilum rostratum in an immunocompetent host. Arch Dermatol 1987;123(10):1346-50
   PubMedGoogle Scholar
• Clancy CJ, Wingard JR, Hong Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. Med Mycol 2000;38(2):169-75
   PubMedGoogle Scholar
• Thompson GR III, Patterson TF. Pulmonary aspergillosis: recent advances. Semin Respir Crit Care Med 2011;32(6):673-81
   PubMedGoogle Scholar
• van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998;36(11):3115-21
   PubMedGoogle Scholar
• Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):696-709
   PubMed Web of Science ®Google Scholar
• Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987;317(18):1105-8
   PubMedGoogle Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60
   PubMed Web of Science ®Google Scholar
• Neuville S, Dromer F, Morin O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003;36(3):337-47
   PubMedGoogle Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50(3):291-322
   PubMed Web of Science ®Google Scholar
• Thompson GR III, Wiederhold NP, Fothergill AW, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009;53(1):309-11
   PubMed Web of Science ®Google Scholar
• Bartlett KH, Cheng PY, Duncan C, et al. A decade of experience: Cryptococcus gattii in British Columbia. Mycopathologia 2012;173(5-6):311-19
   PubMedGoogle Scholar
• Hagen F, Illnait-Zaragozi MT, Bartlett KH, et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 2010;54(12):5139-45
   PubMed Web of Science ®Google Scholar
• Thompson GR III, Albert N, Hodge G, et al. Phenotypic Differences of Cryptococcus Molecular Types: implications for virulence in a Drosophila model of infection. Infect Immun 2014;82(7):3058-65
   PubMedGoogle Scholar
• Hay RJ. Fusarium infections of the skin. Curr Opin Infect Dis 2007;20(2):115-17
   PubMedGoogle Scholar
• Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002;35(8):909-20
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5):634-53
   PubMed Web of Science ®Google Scholar
• Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994;19(1):67-76
   PubMedGoogle Scholar
• Cocanour CS, Miller-Crotchett P, Reed RL II, et al. Mucormycosis in trauma patients. J Trauma 1992;32(1):12-15
   PubMedGoogle Scholar
• Chang C, Gershwin ME, Thompson GR III. Fungal disease of the nose and sinuses: an updated overview. Curr Allergy Asthma Rep 2013;13(2):152-61
   PubMedGoogle Scholar
• Thompson GR 3rd, Patterson TF. Fungal disease of the nose and paranasal sinuses. J Allergy Clin Immunol 2012;129(2):321-6
   PubMedGoogle Scholar
• Davis BA. Sporotrichosis. Dermatol Clin 1996;14(1):69-76
   PubMedGoogle Scholar
• Barros MB, de Almeida Paes R, Schubach AO. Sporothrix schenckii and Sporotrichosis. Clin Microbiol Rev 2011;24(4):633-54
   PubMed Web of Science ®Google Scholar
• Reed KD, Moore FM, Geiger GE, Stemper ME. Zoonotic transmission of sporotrichosis: case report and review. Clin Infect Dis 1993;16(3):384-7
   PubMedGoogle Scholar
• Barros MB, Schubach Ade O, do Valle AC, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis 2004;38(4):529-35
   PubMedGoogle Scholar
• Kauffman CA. Sporotrichosis. Clin Infect Dis 1999;29(2):231-6; quiz 7
   PubMedGoogle Scholar
• Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious Diseases Society of A. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45(10):1255-65
   PubMed Web of Science ®Google Scholar
• Thompson GR III, Lewis JS II. Pharmacology and clinical use of voriconazole. Expert Opin Drug Metab Toxicol 2010;6(1):83-94
   PubMed Web of Science ®Google Scholar
• Dickson EC. "Valley Fever" of the San Joaquin Valley and Fungus Coccidioides. Cal West Med 1937;47(3):151-5
   PubMedGoogle Scholar
• Galgiani JN. Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med 1999;130(4 Pt 1):293-300
   PubMedGoogle Scholar
• Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):658-61
   PubMed Web of Science ®Google Scholar
• Thompson GR III. Pulmonary coccidioidomycosis. Semin Respir Crit Care Med 2011;32(6):754-63
   PubMed Web of Science ®Google Scholar
• Drutz DJ, Catanzaro A. Coccidioidomycosis. Part II. Am Rev Respir Dis 1978;117(4):727-71
   PubMedGoogle Scholar
• DiCaudo DJ. Coccidioidomycosis: a review and update. J Am Acad Dermatol 2006;55(6):929-42; quiz 43-5
   PubMedGoogle Scholar
• Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011;53(11):1060-6
   PubMedGoogle Scholar
• Brown EM, McTaggart LR, Zhang SX, et al. Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One 2013;8(3):e59237
   Google Scholar
• Gray NA, Baddour LM. Cutaneous inoculation blastomycosis. Clin Infect Dis 2002;34(10):E44-9
   Google Scholar
• Durkin M, Witt J, Lemonte A, et al. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004;42(10):4873-5
   PubMed Web of Science ®Google Scholar
• Mongkolrattanothai K, Peev M, Wheat LJ, Marcinak J. Urine antigen detection of blastomycosis in pediatric patients. Pediatr Infect Dis J 2006;25(11):1076-8
   PubMed Web of Science ®Google Scholar
• Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008;46(12):1801-12
   PubMed Web of Science ®Google Scholar
• Cockshott WP, Lucas AO. Histoplasmosis Duboisii. Q J Med 1964;33:223-38
   PubMedGoogle Scholar
• Wheat J. Histoplasmosis: recognition and treatment. Clin Infect Dis 1994;19(Suppl 1):S19-27
   PubMed Web of Science ®Google Scholar
• Goodwin RA Jr, Shapiro JL, Thurman GH, et al. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine 1980;59(1):1-33
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45(7):807-25
   PubMed Web of Science ®Google Scholar
• Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993;6(2):89-117
   PubMed Web of Science ®Google Scholar
• Calle D, Rosero DS, Orozco LC, et al. Paracoccidioidomycosis in Colombia: an ecological study. Epidemiol Infect 2001;126(2):309-15
   PubMedGoogle Scholar
• Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008;6(2):251-62
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Goldani LZ, Schlamm HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007;45(11):1462-9
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004;10(Suppl 1):48-66
   PubMed Web of Science ®Google Scholar
• Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1992;14(4):871-4
   PubMedGoogle Scholar
• Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg 2007;77(2):350-3
   PubMed Web of Science ®Google Scholar
• Kenyon C, Bonorchis K, Corcoran C, et al. A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 2013;369(15):1416-24
   PubMedGoogle Scholar
• Anstead GM, Sutton DA, Graybill JR. Adiaspiromycosis causing respiratory failure and a review of human infections due to Emmonsia and Chrysosporium spp. J Clin Microbiol 2012;50(4):1346-54
   PubMedGoogle Scholar
• Thompson GR III, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med 2009;30(2):203-15, v
   PubMed Web of Science ®Google Scholar
• Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006;40(7-8):1456-61
   PubMed Web of Science ®Google Scholar
• Eiden C, Peyriere H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007;41(5):755-63
   PubMed Web of Science ®Google Scholar
• Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45(2):191-3
   PubMed Web of Science ®Google Scholar
• Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(Suppl 3)):S318-26
   Google Scholar
• Stevens DA, Diaz M, Negroni R, et al. Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group. Chemotherapy 1997;43(5):371-7
   PubMedGoogle Scholar
• Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18(2 Pt 1):263-8
   PubMedGoogle Scholar
• Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997;52(3):235-7
   PubMed Web of Science ®Google Scholar
• Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26(4):561-6
   PubMed Web of Science ®Google Scholar
• Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357(9270):1766-7
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000;46(2):229-34
   PubMedGoogle Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42(10):1398-403
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53(3):958-66
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50(5):1881-3
   PubMed Web of Science ®Google Scholar
• Jain R, Pottinger P. The effect of gastric Acid on the absorption of posaconazole. Clin Infect Dis 2008;46(10):1627; author reply -8
   PubMedGoogle Scholar
• Krishna G, Ma L, Martinho M, O’Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012;56(8):4196-201
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012;67(11):2725-30
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36(5):630-7
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15
   PubMed Web of Science ®Google Scholar
• Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014;58(7):997-1002
   PubMed Web of Science ®Google Scholar
• Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010;170(5):291-313
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006;57(1):135-8
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9
   PubMed Web of Science ®Google Scholar
• Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006;27(Suppl 1):12-16
   PubMed Web of Science ®Google Scholar
• Darkes MJ, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 2003;4(1):39-65
   PubMed Web of Science ®Google Scholar
• Ryder NS. Mechanism of action and biochemical selectivity of allylamine antimycotic agents. Ann N Y Acad Sci 1988;544:208-20
   PubMedGoogle Scholar
• De Carli L, Larizza L. Griseofulvin. Mutat Res 1988;195(2):91-126
   PubMedGoogle Scholar
• Rosa FW, Hernandez C, Carlo WA. Griseofulvin teratology, including two thoracopagus conjoined twins. Lancet 1987;1(8525):171
   PubMedGoogle Scholar
• Dodds Ashley ES LR, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43(s1):S28-39
   Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47(3):364-71
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53(1):24-34
   PubMed Web of Science ®Google Scholar
• Mauceri AA, Cullen SI, Vandevelde AG, Johnson JE 3rd. Flucytosine. An effective oral treatment for chromomycosis. Arch Dermatol 1974;109(6):873-6
   PubMedGoogle Scholar
• Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46(4):1032-7
   PubMed Web of Science ®Google Scholar